We have located links that may give you full text access.
Clinical Trial
Journal Article
Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.] 2004 March
BACKGROUND: Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.
OBJECTIVE: To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.
RESULTS: After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor.
CONCLUSION: Imiquimod 5% cream may be another treatment modality for nodular BCC.
OBJECTIVE: To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.
RESULTS: After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor.
CONCLUSION: Imiquimod 5% cream may be another treatment modality for nodular BCC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app